Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
Sasimon BorrirukwisitsakPongchirat TantayakomWanrachada KatchamartPublished in: Clinical rheumatology (2021)
RTX may be effective for lung and skin involvement in SSc, with no serious AEs. However, further studies with high quality and a large sample size are necessary to firmly establish the efficacy and safety of the use of RTX with SSc patients. Key Points • RTX may be an alternative treatment for cutaneous and pulmonary manifestations in patients with SSc with a favorable safety profile. • However, further studies with a high quality and large sample size are necessary to firmly establish its efficacy and safety.
Keyphrases
- systemic sclerosis
- interstitial lung disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- soft tissue
- pulmonary hypertension
- prognostic factors
- case control
- diffuse large b cell lymphoma
- patient reported outcomes
- rheumatoid arthritis
- hodgkin lymphoma
- chronic lymphocytic leukemia